CCM
AGIO icon

Coldstream Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Coldstream Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,365
Closed -$40K – 1158
2025
Q1 		$40K Buy
+1,365
New +$45.3K ﹤0.01% 1816

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coldstream Capital Management's AGIO Position: Q2 2025 in Review

Coldstream Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q2 2025, closing a stake of 1,365 shares — an estimated $40K sold.

Coldstream Capital Management first reported a position in AGIO in Q1 2025 and held it in 1 quarter. The position peaked at $40K in Q1 2025. 214 funds tracked by Wall St. Rank hold AGIO as of Q2 2025.

  • Coldstream Capital Management reported no remaining Agios Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 1,365 Agios Pharmaceuticals shares in Q2 2025, an estimated $40K.
  • Coldstream Capital Management first reported a position in Agios Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Agios Pharmaceuticals position peaked at $40K in Q1 2025.
  • 214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.